Sage TherapeuticsSAGE
About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Employees: 487
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $1.1M
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
1% more funds holding
Funds holding: 175 [Q3] → 176 (+1) [Q4]
0.75% less ownership
Funds ownership: 84.48% [Q3] → 83.74% (-0.75%) [Q4]
14% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 59
26% less capital invested
Capital invested by funds: $375M [Q3] → $278M (-$96.6M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Scotiabank George Farmer 27% 1-year accuracy 6 / 22 met price target | 53%upside $12 | Sector Outperform Maintained | 12 Feb 2025 |
Wedbush Laura Chico 22% 1-year accuracy 12 / 55 met price target | 24%downside $6 | Neutral Reiterated | 12 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 21% 1-year accuracy 7 / 33 met price target | 2%upside $8 | Hold Maintained | 12 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 46 / 179 met price target | 53%upside $12 | Neutral Reiterated | 12 Feb 2025 |
Piper Sandler David Amsellem 51% 1-year accuracy 18 / 35 met price target | 15%upside $9 | Overweight Maintained | 2 Jan 2025 |
Financial journalist opinion
Based on 11 articles about SAGE published over the past 30 days









